



## Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017

October 18, 2017

– Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m. PDT –

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 18, 2017-- [Exelixis, Inc.](#) (NASDAQ:EXEL) announced today that its third quarter 2017 financial results will be released on Wednesday, November 1, 2017 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company's website.

To access the webcast link, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call (855) 793-2457 (domestic) or (631) 485-4921 (international) and provide the conference call passcode 96645455 to join by phone.

A telephone replay will be available until 8:00 p.m. EDT on November 3, 2017. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 96645455. A webcast replay will also be archived on [www.exelixis.com](http://www.exelixis.com) for one year.

### About Exelixis

Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring them to patients globally. With growing revenues from the three resulting commercialized products – CABOMETRYX<sup>®</sup>, COMETRIQ<sup>®</sup>, and COTELLIC<sup>®</sup> – we are reinvesting in our business to maximize the potential of our pipeline, which we intend to supplement with targeted business development activities and internal drug discovery, all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. For more information about Exelixis, please visit [www.exelixis.com](http://www.exelixis.com) or follow @ExelixisInc on Twitter.

*Exelixis, the Exelixis logo, CABOMETRYX, COMETRIQ and COTELLIC are registered U.S. trademarks.*



View source version on businesswire.com: <http://www.businesswire.com/news/home/20171018006466/en/>

Source: Exelixis, Inc.

*Exelixis, Inc.*  
Susan Hubbard, 650-837-8194  
Executive Vice President, Public Affairs & Investor Relations  
[shubbard@exelixis.com](mailto:shubbard@exelixis.com)